Table 1.
Therapy | Phase | Breast cancer Subtype | Site/Sponsor | Clinical Trials.gov | Enrolment |
---|---|---|---|---|---|
Letrozole 2.5mg PO daily + DHEA 500 mg/1000mg PO daily | 1 | ER-Advanced disease in postmenopausal patients | OHSU Knight Cancer Institute | NCT00516542 | Jul 2007–Dec 2010; Terminated due to poor accrual |
Bicalutamide 150mg PO daily | 2 | AR+ TNBC, Advanced disease | Memorial Sloan-Kettering Cancer Center | NCT00468715 | May 2007–Oct 2013; Completed |
Enzalutamide 80mg and 160mg PO daily | 1 | Advanced disease | Medivation | NCT01597193 | May 2012–current; ongoing |
Enzalutamide 160mg PO daily | 2 | AR+ TNBC, Advanced disease | Medivation | NCT01889238 | Jun 2013–current; ongoing |
Abiraterone Acetate | 1/2 | Advanced disease in postmenopausal patients | Cancer Research UK | NCT00755885 | Oct 2008–current, ongoing |
Enobosarm 9mg PO daily | 2 | ER+ advanced disease, in patients who previously responded to hormone therapy | GTx | NCT01616758 | April 2012–current; ongoing |
Abbreviations: DHEA, Dehydroepiandrosterone; TNBC, Triple negative breast cancer.